Literature DB >> 2393277

Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

A K Hurst1, M A Yoshinaga, G H Mitani, K A Foo, R W Jelliffe, E C Harrison.   

Abstract

A Bayesian method for monitoring vancomycin concentrations and adjusting regimens in patients with unstable renal function by using a two-compartment population model was evaluated with a personal computer. The population model was derived from data from 12 cardiac outpatients who received single doses of vancomycin. The performance of the method was then tested in 27 acutely ill patients who received multiple doses of vancomycin. Significant renal impairment was observed in 15 patients. Renal function changed in 15 patients. The vancomycin concentrations in the patients with changing renal function were not at steady state during the observation times. Two concentrations in serum (peak and then trough, or trough and then peak) were fitted along with the population model to individualize the parameter values for each patient. All the subsequent concentrations in serum for each patient were then predicted by using the parameter values for each patient. Future concentrations of 118 serum samples were predicted. The mean absolute prediction error was 3.6 +/- 4.5 micrograms/ml, and the mean prediction error was -0.7 +/- 5.3 micrograms/ml. These results confirm that a two-compartment pharmacokinetic model can be sufficiently individualized with the knowledge of just two concentrations of drug in patient serum; it is possible to predict closely subsequent concentrations in serum, and dosing regimens for individual patients can be well adjusted to achieve the chosen therapeutic goals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393277      PMCID: PMC171778          DOI: 10.1128/AAC.34.6.1165

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Renal excretion of vancomycinin in kidney disease.

Authors:  H E Nielsen; H E Hansen; B Korsager; P E Skov
Journal:  Acta Med Scand       Date:  1975-04

2.  Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models.

Authors:  R D Pryka; K A Rodvold; M Garrison; J C Rotschafer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

3.  Evaluation of a method for initiating vancomycin therapy: experience in 205 patients.

Authors:  K D Lake; C D Peterson
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

4.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

6.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

7.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

8.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

9.  Vancomycin therapy for infective endocarditis.

Authors:  J E Geraci; W R Wilson
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

10.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  23 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.

Authors:  Iona Macdonald; Christine E Staatz; Roger W Jelliffe; Alison H Thomson
Journal:  Ther Drug Monit       Date:  2008-02       Impact factor: 3.681

3.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

4.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Bayesian pharmacokinetic analysis of a gentamicin nomogram in neonates: a retrospective study.

Authors:  Robert E Ariano; Daniel S Sitar; Maria Davi; Sheryl A Zelenitsky
Journal:  Curr Ther Res Clin Exp       Date:  2003-03

6.  Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Authors:  Anaïs Glatard; Laurent Bourguignon; Roger W Jelliffe; Pascal Maire; Michael N Neely; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

Review 7.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Glycopeptides and nephrotoxicity.

Authors:  A W Chow; R M Azar
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.

Authors:  S Payen; R Serreau; A Munck; Y Aujard; Y Aigrain; F Bressolle; E Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.